Chiara Di Loreto
Overview
Explore the profile of Chiara Di Loreto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Candido R, Di Loreto C, Desenzani P, Pantanetti P, Romano C, Settembrini S, et al.
Diabetes Ther
. 2024 Jul;
15(9):1963-1977.
PMID: 39039353
From clinical trials and observational data, oral semaglutide has proven to be the most effective second-line oral therapy for the management of patients with type 2 diabetes. This review aims...
2.
Toletti G, Boaretto A, Di Loreto C, Fornengo R, Gigante A, Perrone G
Front Clin Diabetes Healthc
. 2024 May;
5:1328181.
PMID: 38807703
Background: Self-monitoring of blood glucose (SMBG) is a vital practice for type 2 diabetes (T2DM), and glucometers have the potential to improve therapy adherence. However, characteristics of glucometers improving their...
3.
Di Loreto C, Celleno R, Pezzuto D, Ambrosi F, Bellavita S, Biagini M, et al.
Diabetes Ther
. 2024 Apr;
15(6):1313-1331.
PMID: 38605275
Introduction: Efficacy and safety of the fixed ratio combination of insulin degludec and liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence...
4.
Napoli R, Berra C, Catarig A, Di Loreto C, Donatiello E, Berentzen T, et al.
Diabetes Obes Metab
. 2023 Feb;
25(6):1658-1667.
PMID: 36789682
Aims: SURE Italy, a multicentre, prospective, open-label, observational, real-world study, investigated once-weekly semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials And Methods: Adults with T2D...
5.
Di Loreto C, Minarelli V, Nasini G, Norgiolini R, Del Sindaco P
Diabetes Ther
. 2022 Apr;
13(6):1251.
PMID: 35461397
No abstract available.
6.
Di Loreto C, Minarelli V, Nasini G, Norgiolini R, Del Sindaco P
Diabetes Ther
. 2022 Mar;
13(3):551-567.
PMID: 35230650
Introduction: To complement results of the SUSTAIN program, this study assessed effectiveness and safety of once weekly subcutaneous semaglutide in people with type 2 diabetes (T2D) managed under routine care....
7.
Ponzani P, Berra C, Di Lelio A, Del Sindaco P, Di Loreto C, Reggiani F, et al.
Diabetes Ther
. 2019 Nov;
11(1):97-105.
PMID: 31707573
Introduction: Real-world evidence on the effectiveness and safety of insulin degludec (IDeg) in patients with diabetes is a priority. We have therefore evaluated the effectiveness and safety of IDeg, including...
8.
Ponzani P, Berra C, Di Lelio A, Del Sindaco P, Di Loreto C, Reggiani F, et al.
Diabetes Ther
. 2018 Sep;
9(6):2209-2218.
PMID: 30242611
Introduction: Real-world evidence on effectiveness and safety of insulin degludec (IDeg) in patients with diabetes is a priority. The aim of the study was to evaluate patterns of use and...
9.
Guescini M, Fatone C, Stocchi L, Guidi C, Potenza L, Ditroilo M, et al.
Nutr Metab Cardiovasc Dis
. 2007 May;
17(5):383-93.
PMID: 17482439
Background And Aim: In this study we developed a new methodology for obtaining human skeletal muscle samples to evaluate gene expression. This approach is based on a fine needle aspiration...
10.
De Feo P, Di Loreto C, Ranchelli A, Fatone C, Gambelunghe G, Lucidi P, et al.
Acta Biomed
. 2006 Aug;
77 Suppl 1:14-7.
PMID: 16921608
Physical activity activates has acute and chronic effects on glucose, lipid and protein metabolism. In type 1 diabetic subjects, the lack of the physiological inhibition of insulin secretion during exercise...